Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding the market benchmark by more than 15% over the next 6-12 months [4]. Core Insights - The company achieved a total revenue of 15.213 billion yuan in 2025, representing a year-on-year growth of 26.46%, and a net profit attributable to shareholders of 1.764 billion yuan, up 19.87% year-on-year [1]. - In Q4 2025, the company reported revenue of 4.610 billion yuan, a 34.10% increase year-on-year and a 16.45% increase quarter-on-quarter, with a net profit of 579 million yuan, reflecting a 27.27% year-on-year growth and a 39.50% quarter-on-quarter growth [1]. - The company benefits from high capacity utilization and competitive advantages in raw material procurement and cost control, which helped mitigate the impact of rising raw material prices [1]. - The humanoid robot industry is experiencing rapid commercialization, with global shipments expected to reach approximately 18,000 units in 2025, a year-on-year growth of about 508% [2]. - The company has a comprehensive layout in humanoid robots, focusing on three main product areas: rotary joints, linear joints, and dexterous hands, with ongoing projects in lightweight harmonic reducers and integrated joint modules [2]. - The company is optimizing its global resource allocation, shifting projects to locations with supply chain advantages, which will accelerate overseas capacity release and benefit from global growth in the new energy sector [3]. Financial Summary - The company forecasts revenues of 19.038 billion yuan in 2026, with a growth rate of 25.14%, and net profits of 2.381 billion yuan, reflecting a growth rate of 34.97% [3]. - The projected earnings per share (EPS) for 2026 is 8.63 yuan, with a price-to-earnings (P/E) ratio of 20 [3]. - Key financial metrics indicate a stable growth trajectory, with a projected return on equity (ROE) of 15.8% in 2026 and a net profit margin of 12.5% [9].